Search

Your search keyword '"San-Miguel, J. F."' showing total 839 results
Start Over Author "San-Miguel, J. F."
839 results on '"San-Miguel, J. F."'

59. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Author

de Larrea, Fernandez C, Kyle, R A, Durie, B GM, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Blade, J, Orlowski, R Z, and Shah, J J

Published
2013
Full Text
View/download PDF

60. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

Author

Paiva, B, Gutierrez, N-C, Chen, X, Vídriales, M-B, Montalbán, M-Á, Rosiñol, L, Oriol, A, Martínez-López, J, Mateos, M-V, López-Corral, L, Diaz-Rodriguez, E, Pérez, J-J, Fernández-Redondo, E, de Arriba, F, Palomera, L, Bengoechea, E, Terol, M-J, de Paz, R, Martin, A, Hernandez, J, Orfao, A, Lahuerta, J-J, Blade, J, Pandiella, A, and San Miguel, J-F

Published
2012
Full Text
View/download PDF

68. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

Author

Rodríguez-Otero, P., Mateos, M. V., Martínez-López, J., Hernández, M. T., Ocio, E. M., Rosiñol, L., Martínez, R., Teruel, A. I., Gutiérrez, N. C., Bargay, Joan, Bengoechea, Enrique, González, Y., Perez de Oteyza, Jaime, Gironella, Mercedes, Nuñez-Córdoba, J. M., Encinas, C., Martín, Jesús, Cabrera, Carlos, Palomera, L., De Arriba, Felipe, Cedena, María Teresa, Puig, N., Oriol, Albert, Paiva, Bruno, Bladé Creixenti, Juan, Lahuerta, J. J., San Miguel, J. F., Universitat Autònoma de Barcelona, Institut Català de la Salut, [Rodríguez-Otero P] Clínica Universidad de Navarra, Pamplona, Spain. [Mateos MV, Ocio EM] Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain. [Martínez-López J] Hospital Universitario 12 de Octubre, Instituto de Investigación 12 de Octubre, Madrid, Spain. [Hernández MT] Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Rosiñol L] Hospital Clinic I Provincial, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. [Gironella M] Hospital Universitari Vall d'Hebron, Barcelona, Spain., and Vall d'Hebron Barcelona Hospital Campus

Subjects
Oncology, Male, Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores], medicine.medical_specialty, MRD Negativity, humanos, Population, gammopatía monoclonal de relevancia indeterminada, mieloma múltiple, lcsh:RC254-282, Biological Factors::Biomarkers [CHEMICALS AND DRUGS], Transplant ineligible, Monoclonal Gammopathy of Undetermined Significance, Article, Persones grans, factores biológicos::biomarcadores [COMPUESTOS QUÍMICOS Y DROGAS], Other subheadings::Other subheadings::/prevention & control [Other subheadings], 03 medical and health sciences, 0302 clinical medicine, Text mining, Internal medicine, medicine, neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple [ENFERMEDADES], Humans, education, personas::Grupos de Edad::adulto::anciano [DENOMINACIONES DE GRUPOS], Multiple myeloma, Aged, anciano, education.field_of_study, business.industry, Mieloma múltiple - Prognosi, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [DISEASES], Hematology, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Predictive value, Disease control, Novel agents, Persons::Age Groups::Adult::Aged [NAMED GROUPS], 030220 oncology & carcinogenesis, Marcadors bioquímics, Female, business, Multiple Myeloma, 030215 immunology
Abstract

Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) >= 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb >= 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years., This study was supported by the Centro de Investigacion Biomedica en Red-Area de Oncologia-del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369 and CB16/12/00377), Instituto de Salud Carlos III/Subdireccion General de Investigacion Sanitaria (FIS no. PS09/01897/01370, PI12/01761, PI12/02311, PI13/01469, PI14/01867, G03/136, CD13/00340), Asociacion Espanola Contra el Cancer (GCB120981SAN) and the European Research Council (ERC) 2015 Starting Grant (MYELOMANEXT).

Published
2019

69. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma

Author

López-Corral, L., Caballero Velazquez, Teresa, López-Godino, O., Rosiñol, L., Pérez-Vicente, S., Fernandez Aviles, Francesc, Krsnik, Isabel, Morillo, Daniel, Heras, Inmaculada, Morgades, Mireia, Rifon, J. J., Sampol, Antonia, Iniesta, F., Ocio, E. M., Martin, J., Rovira Tarrats, Montserrat, Cabero, M., Castilla-Llorente, C., Ribera, Jose-Maria, Torres-Juan, M., Moraleda, J. M., Martinez, C., Vázquez, A., Gutierrez, G., Caballero, Dolores, San Miguel, J. F., Mateos, M. V., Pérez-Simón, José Antonio, and Universitat Autònoma de Barcelona

Subjects
Oncology, inhibidores del proteasoma, Male, trasplante de células madre hematopoyéticas, medicine.medical_treatment, humanos, Graft vs Host Disease, Hematopoietic stem cell transplantation, Disease, Allo-HSCT, estudios de seguimiento, Recurrence, immune system diseases, Multiple myeloma, Proteasome inhibitor, supervivencia sin enfermedad, mediana edad, anciano, Allogeneic hematopoietic stem, Incidence (epidemiology), Incidence, Hematopoietic Stem Cell Transplantation, Hematology, adulto, Middle Aged, Allografts, Survival Rate, surgical procedures, operative, Toxicity, Allogeneic hematopoietic stem cell transplantation, Female, Stem cell, Proteasome Inhibitors, medicine.drug, Adult, medicine.medical_specialty, mieloma múltiple, incidencia, Disease-Free Survival, Internal medicine, medicine, Humans, Immunologic Factors, factores inmunitarios, tasa de supervivencia, Immunomodulatory drug, Aged, Retrospective Studies, Transplantation, business.industry, estudios retrospectivos, medicine.disease, aloinjertos, Spain, enfermedad injerto contra huésped, Cell transplantation, business, recurrencia, Follow-Up Studies
Abstract

Multiple myeloma (MM) remains as an incurable disease and, although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative approach, most patients ultimately relapse, and their treatment remains challenging. Because allo-HSCT can modify not only the biology of the disease, but also the immune system and the microenvironment, it can potentially enhance the response to rescue therapies. Information on the efficacy and safety of novel drugs in patients relapsing after allo-HSCT is lacking, however. The objectives of this study were to evaluate the efficacy and toxicity of rescue therapies in patients with MM who relapsed after allo-HSCT, as well as to compare their efficacy before and after allo-HSCT. This retrospective multicenter study included 126 consecutive patients with MM who underwent allo-HSCT between 2000 and 2013 at 8 Spanish centers. All patients engrafted. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was 47%, and nonrelapse mortality within the first 100 days post-transplantation was 13%. After a median follow-up of 92 months, overall survival (OS) was 51% at 2 years and 43% at 5 years. The median progression-free survival after allo-HSCT was 7 months, whereas the median OS after relapse was 33 months. Patients relapsing in the first 6 months after transplantation had a dismal prognosis compared with those who relapsed later (median OS, 11 months versus 120 months; P < .001). The absence of chronic GVHD was associated with reduced OS after relapse (hazard ratio, 3.44; P < .001). Most patients responded to rescue therapies, including proteasome inhibitors (PIs; 62%) and immunomodulatory drugs (IMiDs; 77%), with a good toxicity profile. An in-depth evaluation, including the type and intensity of PI- and IMiD-based combinations used before and after allo-HSCT, showed that the overall response rate and duration of response after allo-HSCT were similar to those seen in the pretransplantation period. Patients with MM who relapse after allo-HSCT should be considered candidates for therapy with new drugs, which can achieve similar response rates with similar durability as seen in the pretransplantation period. This pattern does not follow the usual course of the disease outside the transplantation setting, where response rates and time to progression decreases with each consecutive line of treatment. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

Published
2019

91. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

Author

Ludwig, H. Delforge, M. Facon, T. Einsele, H. Gay, F. Moreau, P. Avet-Loiseau, H. Boccadoro, M. Hajek, R. Mohty, M. Cavo, M. Dimopoulos, M. A. San-Miguel, J. F. Terpos, E. Zweegman, S. Garderet, L. Mateos, M.-V. Cook, G. Leleu, X. Goldschmidt, H. Jackson, G. Kaiser, M. Weisel, K. van de Donk, N. W. C. J. Waage, A. Beksac, M. Mellqvist, U. H. Engelhardt, M. Caers, J. Driessen, C. Sonneveld, P.

Abstract

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drugs classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.Leukemia accepted article preview online, 18 December 2017. doi:10.1038/leu.2017.353.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results